Announced Tue, 15 Sept, 2026 · 15:59 IST
Novartis India outlines growth strategy at first investor meet post takeover
Mgmt Guided Margin PressurePromoter Disclosed Acquisition PlansAnalyst Day Multiyear TargetsMgmt Evaded Key QuestionInvestor Communications View source PDFExplain this filing
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-4.4%1-day move
₹2191.00
prior close
₹2164.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.7-2.5-3.4-7.4-4.4-7.1-8.3-9.4-7.3-9.2-8.3———
Up moveDown movePending
AI summary
At first investor meet after ChrysCapital 70.68 percent takeover, new CEO Dr Vikas Gupta outlined plans to double revenue in 4-5 years from about INR650 crores annualized base. Focus on 6 therapy areas including cardiology, pain, ophthalmology. Acquired Minipress XL from Pfizer and in-licensed Pagenax and Accentrix. Near-term costs to rise by INR40-50 crores per quarter. Plans company name change.
Likely market impact
Revenue doubling target in 4-5 years; near-term costs of INR40-50 crores per quarter may pressure margins. Stock could re-rate on growth visibility.